Publications

Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Search by Program

O'Donnell J, Maloney K, Steidler M, Morrison R and Isaacs R

A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science (2021)

Papp-Wallace KM, Shapiro AB, Becka SA, Zeiser ET, LiPuma JJ, Lane DJ, Panchal RG, Mueller JP, O'Donnell JP, and Miller AA

In vitro activity and in vivo efficacy of sulbactam-durlobactam against pathogenic Burkholderia species

Antimicrobial Agents and Chemotherapy (2021)

Lickliter JD, Lawrence K, O’Donnell J, and Isaacs R

Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects

Antimicrobial Agents and Chemotherapy (2020)

Seifert H, Muller C, Stefanik D, Higgins PG, Miller A and Kresken M

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy (2020)

Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, and Reinhart H

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy (2020)

Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O’Donnell J, Miller A, Isaacs R, and Srinivasan S

Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis

Antimicrobial Agents and Chemotherapy (2020)

McLeod SM, Moussa SH, Hackel MA, and Miller AA

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Antimicrobial Agents and Chemotherapy (2020)

O’Donnell J, Preston RA, Mamikonyan G, Stone E, and Isaacs R

Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects

Antimicrobial Agents and Chemotherapy (2019)

Barnes MD, Kumar V, Bethel CR, Moussa SH, O’Donnell J, Rutter JD, Good CE, Hujer KM, Hujer AM, Marshall SH, Kreiswirth BN, Richter SS, Rather PN, Jacobs MR, Papp-Wallace KM, van den Akker F, and Bonomo RA

Targeting multidrug-resistant Acinetobacter spp.: sulbactam and the diazabicyclooctenone β-lactamase inhibitor ETX2514 as a novel therapeutic agent

mBio (2019)

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, and Stone E

Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects

Antimicrobial Agents and Chemotherapy (2018)